A 66-year-old woman with type 2 diabetes and hypertension has an A1C of 7.9% despite maximally tolerated metformin. She has established atheroscleroti...

Question

A 66-year-old woman with type 2 diabetes and hypertension has an A1C of 7.9% despite maximally tolerated metformin. She has established atherosclerotic cardiovascular disease. According to the 2024 Diabetes Canada pharmacologic update, which class of agent should be prioritised as add-on therapy to improve cardiovascular outcomes?

Accepted Answer

SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Thiazolidinedione

Answer

Basal insulin as second-line therapy for all patients

ca-mccqe1 MCQ (SBA): Pharmacologic management of type 2 diabetes